S
Eric Floyd
VP, Worldwide Regulatory Affairs, Cephalon
BIGGEST HIT: 3 NDAs in one year
ROLE MODEL: Aventis' R&D head Frank Douglas "who moved to Germany, and learned the language and lifestyle to lead a global company"
Eric Floyd pulls no punches about Big Pharma's famous fear of change. "If you think outside the box, you can be viewed as a threat. If you are perceived as a threat, they challenge and frustrate you," he says. That's how Floyd found his way to Cephalon, one of the industry's fastest-growing biotechs
Eric Floyd
Like so much else in pharma, what's required from regulatory has changed so much and so fast that "the old mindsets and models are no longer sustainable," says Floyd. "We're seeing 45-year-old CEOs because they understand the challenges—and because the boards understand it, too."
At Cephalon, he finds the flexibility, fast-response, and forward-thinking that's missing at the large caps—and mandatory at the predictably unpredictable FDA. "We need to anticipate the agency's concerns, and build them into our clinical programs and marketing strategies," he says. "There's no guidance yet with the new REMS, so we need to influence change internally." Given FDA's knockdown of Cephalon's Fentora application for noncancer indications, Floyd will get the chance to have influence as Cephalon ramps up its controls over the prone-to-abuse product in its argument to the agency.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.